Invion Stock

Invion SG&A Expenses

The Selling, General & Administrative Expenses of Invion (IVX.AX) as of Aug 8, 2026 is 2.01 M AUD. In the previous year, Selling, General & Administrative Expenses was 5.62 M AUD — a change of -64.24% (lower).

SG&A Expenses

2.01 MAUD

YoY

-64.24%

Last updated:

Selling, General & Administrative Expenses of Invion is 2026 2.01 M AUD. Selling, General & Administrative Expenses of Invion was 2025 5.62 M AUD. It decreases by -64.24% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Selling, General & Administrative Expenses of Invion is 2.01 M AUD in 2026.

Selling, General & Administrative Expenses of Invion changed from 5.62 M AUD to 2.01 M AUD, representing a -64.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses Invion since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Invion

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Invion